1
Clinical Trials associated with InnoPCVAn Open Label, Prospective, Exploratory Study to Assess the Safety and Efficacy of Individualized Neo-antigen MRNA Cancer Vaccine InnoPCV in Combination with PD-1 in Participants with Advanced Solid Tumor
This is an open-label, prospective, exploratory clinical study, which is divided into two phases: dose escalation phase (Phase Ia) and expansion phase (Phase Ib). After completing the dose-escalation phase (Stage Ia) (5-11 patients), the investigator will select the dose group (RP2D) based on safety, tolerability, and preliminary immune-related characteristics and efficacy data, and choose 2-3 advanced solid tumors to enter the expansion phase (Stage Ib).
100 Clinical Results associated with InnoPCV
100 Translational Medicine associated with InnoPCV
100 Patents (Medical) associated with InnoPCV
100 Deals associated with InnoPCV